Internship

Undergraduate Protein Sciences and Mass Spectrometry Internship

Confirmed live in the last 24 hours

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Princeton, NJ, USA

Potential hybrid work model with onsite presence required.

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • Undergraduate (entering Junior year or above in the Fall of 2025) in chemistry, biochemistry, molecular biology, or a related scientific major.
  • Strong problem-solving ability in experimental design, execution, and data interpretation.
  • Hands-on experience with running HPLC and mass spectrometry instruments is preferred, but not required.
  • Excellent verbal and written communication skills.
Responsibilities
  • Directly contribute to biomarker LC-MS/MS assay development for protein biomarker analysis.
  • Contribute to establishment and optimization of current biomarker LC-MS/MS assay workflows for protein biomarkers analysis.
  • Explore novel technologies in clinical biomarker LC-MS/MS assay development.
  • Participate in group and department meetings to discuss and present research data.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's collaboration with AI Proteins could lead to novel miniprotein-based therapeutics.
  • The $3.5bn agreement with Prime Medicine enhances BMS's cell and gene-therapy pipeline.
  • Karen Costello's appointment may strengthen BMS's commercial strategy in Ireland.

What critics are saying

  • BMS faces legal challenges, including a lawsuit against HRSA and HHS.
  • The dismissal of a $6.4 billion lawsuit could impact BMS's financial standing.
  • Regulatory hurdles may delay the approval of new drugs, affecting market entry.

What makes Bristol-Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?